← Eichor
Condition: Pet Positive Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Pet Positive

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Cancer (LUST)
Phase 2 · 2 location(s) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRS · NCT05893381Early Prostate Cancer Recurrence With PSMA PET Positive Unilateral Pelvic Lesion(s)
NA · 1 location(s) · Martini-Klinik am UKE GmbH · NCT04271579Gene Expression Profiles in Spinal Tuberculosis.
Phase N/A · 1 location(s) · University of Cape Town · NCT0561009868Ga FAPI PET/CT Evaluation of Axillary Lymph Node Status After Neoadjuvant Therapy in Patients With Clinical Axillary L
Phase N/A · 1 location(s) · Kunwei Shen · NCT0655937168-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
Phase 4 · 1 location(s) · Weill Medical College of Cornell University · NCT04081701Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI
Phase 1 · 1 location(s) · University of Alabama at Birmingham · NCT04332588Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Phase 2 · 1 location(s) · University of Wisconsin, Madison · NCT04573231Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06096870Evaluation of [68Ga]Ga-NOTA-anti-HER2-sdAb PET/CT for Predicting Pathological Complete Response After Neoadjuvant Chemot
Phase 2 · 1 location(s) · Centre Henri Becquerel · NCT075939764FMFES-PET Imaging of ER+ Advanced Breast Cancers
Phase 2 · 1 location(s) · Centre de recherche du Centre hospitalier universitaire de S · NCT04824014AI-based pCR Assessment/Prediction in HER2-Positive BC Using PET/MRI
Phase N/A · 1 location(s) · Heinrich-Heine University, Duesseldorf · NCT06708910A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to E
Phase 1/Phase 2 · 1 location(s) · AHS Cancer Control Alberta · NCT03145857[18F]FES PET/CT for the Detection of Distant Metastasis in Low-grade ER-positive Stage III Breast Cancer
Phase 2 · 1 location(s) · Asan Medical Center · NCT0731407368Ga-FAPI-LM3 PET/CT Imaging in Patients With FAP/SSTR2 Positive Disease and Compared With 18F-FDG
NA · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT05873777Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascula
EARLY_Phase 1 · 1 location(s) · Emory University · NCT06914999Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan
Phase 2 · 9 location(s) · Convergent Therapeutics · NCT0654946568Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients
EARLY_Phase 1 · 1 location(s) · Peking Union Medical College Hospital · NCT0554902468Ga-PFA2 PET Imaging for the Diagnosis of Annexin A2-Positive Tumors
Phase N/A · 1 location(s) · Peking University First Hospital · NCT07331532Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT05761366MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myel
Phase N/A · 2 location(s) · MPN Research Foundation · NCT07362225HER2 Expression of HER2 Affibody-based PET/CT to Predict Response in Bladder Cancer Patients Treated With ADC
NA · 1 location(s) · Peking University Cancer Hospital & Institute · NCT0654852968Ga-PSFA PET Imaging in Patients With PSMA/FAP Positive Disease
EARLY_Phase 1 · 1 location(s) · First Affiliated Hospital of Chongqing Medical University · NCT0638738118F-FDG Versus 68Ga-FAPI-46 as PET Tracer in ER-positive Breast Cancer.
Phase 2 · 1 location(s) · Maastricht University Medical Center · NCT06335069Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer
Phase 2 · 1 location(s) · University of Nebraska · NCT07237269PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate
Phase 2/Phase 3 · 1 location(s) · Affidea Nu-med Center of Oncological DIagnostics and Therapy · NCT074260943'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Posit
Phase 2 · 2 location(s) · City of Hope Medical Center · NCT06260033FES BPET-DBT in Newly Diagnosed Breast Cancer
EARLY_Phase 1 · 1 location(s) · Abramson Cancer Center at Penn Medicine · NCT05659797Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma
Phase 1 · 1 location(s) · Robert Flavell, MD, PhD · NCT05892393Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer
Phase 4 · 1 location(s) · Weill Medical College of Cornell University · NCT06072807
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.